利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

10 条记录 (耗时 0.047 秒)

    3,3-disubstituted tetrahydropyranyl cyclopentyl amide modulators of chemokine receptor activity
    2.
    发明授权
    3,3-disubstituted tetrahydropyranyl cyclopentyl amide modulators of chemokine receptor activity 失效
    趋化因子受体活性的3,3-二取代四氢吡喃基环戊基酰胺调节剂

    公开(公告)号：US07566726B2

    公开(公告)日：2009-07-28

    申请号：US11587448

    申请日：2005-04-22

    申请人： Lihu Yang ,  Sander G. Mills ,  Kothandaraman Shankaran

    发明人： Lihu Yang ,  Sander G. Mills ,  Kothandaraman Shankaran

    IPC分类号： C07D217/02 ,  C07D471/02 ,  A61K31/4375

    CPC分类号： C07D471/04

    摘要： (wherein n, R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R15, R16, R17, R18, Y and Z are defined herein) which are modulators of chemokine receptor activity and are useful in the prevention or treatment of certain inflammatory and immunoregulatory disorders and diseases, allergic diseases, atopic conditions including allergic rhinitis, dermatitis, conjunctivitis, and asthma, as well as autoimmune pathologies such as rheumatoid arthritis and atherosclerosis. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which chemokine receptors are involved.

    摘要翻译： （其中n，R 1，R 2，R 3，R 4，R 5，R 6，R 7，R 8，R 9，R 10，R 15，R 16，R 17，R 18，Y和Z在本文中定义），其是趋化因子受体活性的调节剂， 预防或治疗某些炎性和免疫调节性疾病和疾病，过敏性疾病，特应性病症，包括过敏性鼻炎，皮炎，结膜炎和哮喘，以及自身免疫病态如类风湿性关节炎和动脉粥样硬化。 本发明还涉及包含这些化合物的药物组合物以及这些化合物和组合物在预防或治疗涉及趋化因子受体的疾病中的用途。

    Hexahydro-5-imino-1,4-1,4-thiazepine derivatives as inhibitors of nitric oxide synthases
    6.
    发明授权
    Hexahydro-5-imino-1,4-1,4-thiazepine derivatives as inhibitors of nitric oxide synthases 失效
    六氢-5-亚氨基-1,4-1,4-硫杂衍生物作为一氧化氮合酶的抑制剂

    公开(公告)号：US06372733B1

    公开(公告)日：2002-04-16

    申请号：US09477246

    申请日：2000-01-04

    申请人： Charles G. Caldwell ,  Malcolm Maccoss ,  William K. Hagmann ,  Shrenik K. Shah ,  Kothandaraman Shankaran ,  Karla L. Furman

    发明人： Charles G. Caldwell ,  Malcolm Maccoss ,  William K. Hagmann ,  Shrenik K. Shah ,  Kothandaraman Shankaran ,  Karla L. Furman

    IPC分类号： C07D2806

    CPC分类号： C07D281/06 ,  C07D243/08 ,  C07D267/16 ,  C07D337/04

    摘要： Disclosed herein are compounds of Formula I and pharmaceutically acceptable salts thereof which have been found useful in the treatment of nitric oxide synthase mediated diseases and disorders, including neurodegenerative disorders, disorders of gastrointestinal motility and inflammation. These diseases and disorders include hypotension, septic shock, toxic shock syndrome, hemodialysis, IL-2 therapy such as in in cancer patients, cachexia, immunosuppression such as in transplant therapy, autoimmune and/or inflammatory indications including sunburn, eczema or psoriasis and respiratory conditions such as bronchitis, asthma, oxidant-induced lung injury and acute respiratory distress (ARDS), glomerulonephritis, restenosis, inflammatory sequelae of viral infections, myocarditis, heart failure, atherosclerosis, osteoarthritis, rheumatoid arthritis, septic arthritis, chronic or inflammatory bowel disease, ulcerative colitis, Crohn's disease, systemic lupus erythematosis (SLE), ocular conditions such as ocular hypertension, retinitis and uveitis, type 1 diabetes, insulin-dependent diabetes mellitus and cystic fibrosis.

    摘要翻译： 本发明公开了已发现可用于治疗一氧化氮合酶介导的疾病和病症（包括神经退行性疾病，胃肠蠕动和炎症病症）的式I化合物及其药学上可接受的盐。 这些疾病和障碍包括低血压，脓毒性休克，中毒性休克综合征，血液透析，诸如癌症患者中的IL-2治疗，恶病质，免疫抑制如移植治疗，自身免疫和/或炎性指征，包括晒伤，湿疹或银屑病和呼吸 诸如支气管炎，哮喘，氧化剂诱发的肺损伤和急性呼吸窘迫（ARDS），肾小球性肾炎，再狭窄，病毒感染的炎症后遗症，心肌炎，心力衰竭，动脉粥样硬化，骨关节炎，类风湿性关节炎，脓毒性关节炎，慢性或炎性肠病 溃疡性结肠炎，克罗恩病，系统性红斑狼疮（SLE），眼部疾病如眼高压，视网膜炎和葡萄膜炎，1型糖尿病，胰岛素依赖性糖尿病和囊性纤维化。

    3,3-Disubstituted Tetrahydropyranyl Cyclopentyl Amide Modulators Of Chemokine Receptor Activity
    8.
    发明申请
    3,3-Disubstituted Tetrahydropyranyl Cyclopentyl Amide Modulators Of Chemokine Receptor Activity 失效
    趋化因子受体活性的3,3-二取代四氢吡喃基环戊酰胺调节剂

    公开(公告)号：US20080021057A1

    公开(公告)日：2008-01-24

    申请号：US11587448

    申请日：2005-04-22

    申请人： Lihu Yang ,  Sander Mills ,  Kothandaraman Shankaran

    发明人： Lihu Yang ,  Sander Mills ,  Kothandaraman Shankaran

    IPC分类号： A61K31/4375 ,  A61P19/02 ,  A61P29/00 ,  A61P37/00 ,  C07D221/02

    CPC分类号： C07D471/04

    摘要： Compounds of Formula I (wherein n, R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R15, R16, R17, R18, Y and Z are defined herein) which are modulators of chemokine receptor activity and are useful in the prevention or treatment of certain inflammatory and immunoregulatory disorders and diseases, allergic diseases, atopic conditions including allergic rhinitis, dermatitis, conjunctivitis, and asthma, as well as autoimmune pathologies such as rheumatoid arthritis and atherosclerosis. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which chemokine receptors are involved.

    摘要翻译： 式I化合物（其中n，R 1，R 2，R 3，R 4，R 4， R 5，R 6，R 7，R 8，R 9，R 9， R 10，R 15，R 16，R 17，R 18，Y和 Z定义为趋化因子受体活性的调节剂，并且可用于预防或治疗某些炎症和免疫调节性疾病和疾病，过敏性疾病，特应性病症，包括过敏性鼻炎，皮炎，结膜炎和哮喘以及自身免疫病理学 如类风湿关节炎和动脉粥样硬化。 本发明还涉及包含这些化合物的药物组合物以及这些化合物和组合物在预防或治疗涉及趋化因子受体的疾病中的用途。

    Tetrahydropyranyl Cyclopentyl 1-Substituted and 1,1-Disubstituted Tetrahydroisoquinoline Modulators of Chemokine Receptor Activity
    9.
    发明申请
    Tetrahydropyranyl Cyclopentyl 1-Substituted and 1,1-Disubstituted Tetrahydroisoquinoline Modulators of Chemokine Receptor Activity 审中-公开
    趋化因子受体活性的四氢吡喃基环戊基1-取代和1,1-二取代四氢异喹啉调节剂

    公开(公告)号：US20070299104A1

    公开(公告)日：2007-12-27

    申请号：US11587314

    申请日：2005-04-22

    申请人： Lihu Yang ,  Sander Mills ,  Gregori Moriello ,  Deodialsingh Guiadeen ,  Kothandaraman Shankaran

    发明人： Lihu Yang ,  Sander Mills ,  Gregori Moriello ,  Deodialsingh Guiadeen ,  Kothandaraman Shankaran

    IPC分类号： A61K31/4709 ,  A61P19/02 ,  C07D217/04 ,  C07D217/24

    CPC分类号： C07D471/04 ,  C07D405/12

    摘要： Compounds of Formula I: I (wherein n, R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R15, R16, Y and Z are as defined herein) which are modulators of chemokine receptor activity and are useful in the prevention or treatment of certain inflammatory and immunoregulatory disorders and diseases, allergic diseases, atopic conditions including allergic rhinitis, dermatitis, conjunctivitis, and asthma, as well as autoimmune pathologies such as rheumatoid arthritis and atherosclerosis. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which chemokine receptors are involved.

    摘要翻译： 式I化合物：I（其中n，R 1，R 2，R 3，R 4， R 5，R 6，R 7，R 8，R 9， R 10，R 15，R 16，Y和Z如本文所定义），其是趋化因子受体活性的调节剂，并且可用于 预防或治疗某些炎性和免疫调节性疾病和疾病，过敏性疾病，特应性病症，包括过敏性鼻炎，皮炎，结膜炎和哮喘，以及自身免疫性病态如类风湿性关节炎和动脉粥样硬化。 本发明还涉及包含这些化合物的药物组合物以及这些化合物和组合物在预防或治疗涉及趋化因子受体的疾病中的用途。

    Hexahydro-5-imino-1,4-heteroazepine derivatives as inhibitors of nitric oxide synthases
    10.
    发明授权
    Hexahydro-5-imino-1,4-heteroazepine derivatives as inhibitors of nitric oxide synthases 失效
    六氢-5-亚氨基-1,4-异吖啶衍生物作为一氧化氮合酶的抑制剂

    公开(公告)号：US6043358A

    公开(公告)日：2000-03-28

    申请号：US721784

    申请日：1996-09-25

    申请人： Charles G. Caldwell ,  William K. Hagmann ,  Malcolm Maccoss ,  Shrenik K. Shah ,  Kothandaraman Shankaran ,  Karla L. Furman

    发明人： Charles G. Caldwell ,  William K. Hagmann ,  Malcolm Maccoss ,  Shrenik K. Shah ,  Kothandaraman Shankaran ,  Karla L. Furman

    IPC分类号： A61P15/10 ,  C07D243/08 ,  C07D267/16 ,  C07D281/06 ,  C07D337/04 ,  C07D267/10 ,  C07D267/12 ,  C07D267/14

    CPC分类号： C07D281/06 ,  C07D243/08 ,  C07D267/16 ,  C07D337/04

    摘要： Disclosed herein are compounds of Formula I and pharmaceutically acceptable salts thereof which have been found useful in the treatment of nitric oxide synthase mediated diseases and disorders, including neurodegenerative disorders, disorders of gastrointestinal motility and inflammation. These diseases and disorders include hypotension, septic shock, toxic shock syndrome, hemodialysis, IL-2 therapy such as in in cancer patients, cachexia, immunosuppression such as in transplant therapy, autoimmune and/or inflammatory indications including sunburn, eczema or psoriasis and respiratory conditions such as bronchitis, asthma, oxidant-induced lung injury and acute respiratory distress (ARDS), glomerulonephritis, restenosis, inflammatory sequelae of viral infections, myocarditis, heart failure, atherosclerosis, osteoarthritis, rheumatoid arthritis, septic arthritis, chronic or inflammatory bowel disease, ulcerative colitis, Crohn's disease, systemic lupus erythematosis (SLE), ocular conditions such as ocular hypertension, retinitis and uveitis, type 1 diabetes, insulin-dependent diabetes mellitus and cystic fibrosis.

    摘要翻译： 本文公开了已经发现可用于治疗一氧化氮合酶介导的疾病和病症的式I化合物及其药学上可接受的盐，所述疾病和病症包括神经变性疾病，胃肠蠕动和炎症病症。 这些疾病和障碍包括低血压，脓毒性休克，中毒性休克综合征，血液透析，诸如癌症患者中的IL-2治疗，恶病质，免疫抑制如移植治疗，自身免疫和/或炎性指征，包括晒伤，湿疹或银屑病和呼吸 诸如支气管炎，哮喘，氧化剂诱发的肺损伤和急性呼吸窘迫（ARDS），肾小球性肾炎，再狭窄，病毒感染的炎症后遗症，心肌炎，心力衰竭，动脉粥样硬化，骨关节炎，类风湿性关节炎，脓毒性关节炎，慢性或炎性肠病 溃疡性结肠炎，克罗恩病，系统性红斑狼疮（SLE），眼部疾病如眼高压，视网膜炎和葡萄膜炎，1型糖尿病，胰岛素依赖性糖尿病和囊性纤维化。